Cetirizine Hydrochloride Patent Expiration

1. Children's Zyrtec Allergy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6455533 J AND J CONSUMER INC Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
Jul, 2018

(6 years ago)




Market Authorisation Date: 30 November, 2020

Treatment: Treatment of seasonal and perennial allergic rhinitis symptoms

Dosage: TABLET, CHEWABLE

How can I launch a generic of CHILDREN'S ZYRTEC ALLERGY before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ZYRTEC ALLERGY family patents

Family Patents

2. Children's Zyrtec Hives Relief patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6455533 J AND J CONSUMER INC Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
Jul, 2018

(6 years ago)




Market Authorisation Date: 30 November, 2020

Treatment: Treatment of seasonal and perennial allergic rhinitis symptoms

Dosage: TABLET, CHEWABLE

How can I launch a generic of CHILDREN'S ZYRTEC HIVES RELIEF before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ZYRTEC HIVES RELIEF family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Quzyttir patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180090 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(5 years from now)

US8513259 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(5 years from now)

US9119771 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(5 years from now)

US8263581 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(5 years from now)

US8314083 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 04, 2022

Market Authorisation Date: 04 October, 2019

Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...

Dosage: SOLUTION

More Information on Dosage

QUZYTTIR family patents

Family Patents

4. Zerviate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993471 HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Mar, 2030

(5 years from now)

US8829005 HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Mar, 2030

(5 years from now)

US9750684 HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Mar, 2030

(5 years from now)

US8829005

(Pediatric)

HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Sep, 2030

(6 years from now)

US9254286 HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Jul, 2032

(7 years from now)

US9254286

(Pediatric)

HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) May 30, 2020
Pediatric Exclusivity(PED) Nov 30, 2020

Market Authorisation Date: 30 May, 2017

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS

More Information on Dosage

ZERVIATE family patents

Family Patents